The Nationwide Inpatient Samples and State Inpatient Databases (2001-2006) were accessed to document the number and type of aneurysm repairs (EVAR versus open). Multiple metrics pertaining to clinical risk factors, socioeconomic status, access to care, provider distribution, and local healthcare capacity were quantitated for each state. We performed bivariate analysis, Pearson (PC) or Spearman (SC) correlations, and multiple regression modeling.
Results: The total number of aneurysms repaired has not find more changed significantly (from 45,828 in 2001 to 45,111 in 2006). Over the same interval, the number of open AAA repair nationwide decreased by 48% while the number of AAA repaired endovascularly increased by 105%. In 2005, the utilization
rate of EVAR among 29 states ranged widely from 39.3% to 69.9%. Use of EVAR was highest in states with higher incidences of aneurysms (PC = 0.43, P < .05), greater number of deaths from heart disease (PC = 0.42, P < .05), greater number of diabetes selleck products discharges (PC = 0.48, P < .005), higher number of carotid stenosis discharges (PC = 0.40, P < .05), and higher number of chronic obstructive pulmonary disorder (COPD) discharges (SC = 0.43, P < .05). Regional malpractice pressure, specifically the number of paid claims and mean malpractice premium, both exhibited positive correlations
with the EVAR rate. The number of physicians, vascular surgeons, hospital beds, teaching hospitals, Cediranib (AZD2171) or trauma centers did not predict high utilization of EVAR nor did the other socio-economic indices tested.
Conclusion: While there was substantial regional variation in the use of EVAR, utilization of the less morbid procedure was well correlated with higher risk populations (number of diabetic patients and deaths secondary to heart disease). Contrary to other studies of regional discrepancies in the utilization of some surgical procedures, it appears that the utilization of EVAR was not associated with physician distribution, socioeconomics, or other non-medical factors. (J Vase Surg 2010;51:801-9.)”
“Corticotropin-releasing factor (CRF) plays a major role in controlling the body’s response to stress. Because painful conditions are inherently stressful, we hypothesize that CRF May act via CRF-1 receptors to contribute to the pain experience. Studies were designed to investigate whether blocking CRF-1 receptors with selective antagonists or reducing their expression with CRF-Saporin, would attenuate ulcer, inflammatory- and neuropathic-like pain. Five experimental designs were undertaken.